GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Catalyst Pharmaceuticals Inc (FRA:CN2) » Definitions » Notes Receivable

Catalyst Pharmaceuticals (FRA:CN2) Notes Receivable : €0.0 Mil (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Catalyst Pharmaceuticals Notes Receivable?

Catalyst Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2024 was €0.0 Mil.


Catalyst Pharmaceuticals Notes Receivable Historical Data

The historical data trend for Catalyst Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Catalyst Pharmaceuticals Notes Receivable Chart

Catalyst Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Catalyst Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Catalyst Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Catalyst Pharmaceuticals Notes Receivable Related Terms

Thank you for viewing the detailed overview of Catalyst Pharmaceuticals's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Catalyst Pharmaceuticals (FRA:CN2) Business Description

Traded in Other Exchanges
Address
355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals (FRA:CN2) Headlines

No Headlines